Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease

Am J Hematol. 2020 Jun;95(6):E151-E153. doi: 10.1002/ajh.25798. Epub 2020 Apr 15.

Authors

Seah H Lim^{1

2}, Dibyendu Dutta^{1

2}

Affiliations

¹ Division of Hematology and Hemostasis, Department of Medicine, New York Medical College, Valhalla, New York, USA.
² Westchester Medical Center Cancer Institute, Hawthorne, New York, USA.

PMID: 32243610
DOI: 10.1002/ajh.25798

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adult
Anemia, Sickle Cell / drug therapy*
Female
Humans
Male
Rifaximin / administration & dosage*
Rifaximin / adverse effects*

Substances

Rifaximin